SanFran,

I think you are reading too much into the efficacy comment. In my opinion (of course I can't speak for the DSMB), as long as apabetalone is not INCREASING the incidence of 3-point MACE events or all-cause mortality, then there should be no efficacy concerns. I don't think the statement in today's news release can be interpreted as indicating that apabetalone is decreasing 3-point MACE events. The futility analysis around mid 2017 will be the first true assessment of whether apabetalone is trending towards decreaseing 3-point MACE events.

BearDownAZ